SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) -- The transaction is subject to customary closing ...

Mordor Intelligence has published a new report on the Pharmaceutical Contract Manufacturing Organization (CMO) Market, offering a comprehensive analysis of trends, growth drivers, and future ...

Recipharm, a global CDMO, has developed a new, dedicated manufacturing facility in support of the latest FDA regulatory ...

The buyer is Siegfried Holding AG, a global contract development and manufacturing organization for the pharmaceutical industry.

The CDMO market offers growth opportunities via increasing demand for biologic therapies and strategic collaborations due to rising drug complexity and strong R&D funding. Challenges include supply ...

The pharmaceutical CMO market thrives on increased outsourcing due to strategic realignment and advanced therapy approvals. Expanding in Asia-Pacific and integrated service offerings further drive ...

The "Contract Pharmaceutical Manufacturing, Research, and Packaging Market Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering. This report aims to provide in-depth knowledge ...

The pharmaceutical contract manufacturing market offers growth via strategic partnerships for innovation, advanced ...

Market growth underscores rising demand for data integrity, automation, and compliance-ready digital platforms across global pharmaceutical operationsDelray Beach, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) - ...

Add Yahoo as a preferred source to see more of our stories on Google. HYDERABAD (Reuters) - Indian contract drug manufacturer Suven Pharmaceuticals said on Thursday it will merge with Cohance ...

(MENAFNEditorial) iCrowdNewswire - Nov 13, 2017 Marketsresearch.Biz Published Global Contract Pharmaceutical Manufacturing Market provides a competent and systematic approach of Focusing the Contract ...

Expansion will increase production volume and scale manufacturing capacity for next-gen drugs for metabolic conditions.